AB Therapeutics New Anticancer Compounds Reduce by 70% Lung Tumors Growth

The Barcelona Based Biotech Company is in a Series-A Fundraising Round to Conduct Preclinical Development and to File an IND in Late 2011

BARCELONA, November 10, 2010 - The Barcelona-based biotech company AB Therapeutics has obtained high
efficacy results with its 2 new anticancer compounds in animal models of lung
cancer (NSCLC) using Membrane Lipid Therapy (MLT), a new therapeutic
approach. After 4 weeks treatment in immunosupressed mice, the molecules
reduced tumor growth in treated animals by 70%. Additionally, tumor growth
arrest was observed in 10% of treated mice. Adverse events were markedly
lower than in mice treated with gold standard treatment docetaxel.

AB Therapeutics is in a series-A fundraising round to conduct
preclinical development and to file an IND in 3Q2011 to start phase I
clinical trials in late 2011. Capital needs are 0.8-1 MEUR in 2010, 2.8 MEUR
in 2011 and 5 MEUR in 2012. The company expects to receive 2 MEUR in
government soft loans from European, Spanish and Catalan institutions.

"We are satisfied to have in vivo validation of in vitro results, not
only in efficacy but also in low toxicity," said Jordi Espadaler, PhD, VP
Discovery Research. "The results obtained will allow us to build the
regulatory preclinical package to start clinical trials next year. We have
initiated a series A round of financing to accomplish this goal," said Carles
Domenech, PhD, CEO.

Dr. Domenech highlights that MLT "could represent an important
contribution to human health," and also points at its high market potential:
"Our compounds have blockbuster potential due to the high mortality in lung
cancer, still an unmet medical need."

About Membrane Lipid Therapy

MLT is a new therapeutic approach, with a mechanism of action consisting
in modifying the dynamics of cell membranes, thus altering the activity of
multiple proteins involved in cell growth regulation.

Molecules under preclinical development selectively induce apoptosis in
several cancer types: lung, pancreatic, glioma and leukemia.

About AB Therapeutics

AB Therapeutics, SL is a drug discovery and development company
headquartered in Barcelona, Catalonia, Spain, with planned US facilities in
Boston. The company was cofounded in late 2009 by AB Biotics, SA, a company
publicly traded at the Spanish alternative stock market (MAB), Carles
Domenech (CEO) and Jordi Espadaler (VP Discovery Research).

AB Therapeutics, SL develops safer human therapeutics targeting cell
membranes to treat cancer and other indications with unmet medical needs. It
has a molecule ready to start preclinical development in 4Q2010, with Phase I
clinical trials (first in man) starting in late 2011 / early 2012. A second
drug candidate will start preclinical development in 2Q2011.

    Contact:

    Media relations:
    Nuria Peláez
    Tel. +34-902-903-844
    media.relations@ab-therapeutics.com

    Investors:
    Carles Domènech, PhD
    Tel. +34-935-868-977
    contact@ab-therapeutics.com

Contact: Media relations: Nuria Peláez, Tel. +34-902-903-844, media.relations at ab-therapeutics.com; Investors: Carles Domènech, PhD, Tel. +34-935-868-977, ccontact at ab-therapeutics.com